Delta Sleep-Inducing Peptide (DSIP) dosage in published studies and labels

These are the doses used for Delta Sleep-Inducing Peptide (DSIP) in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: September 5, 2026

Studied regimens and sources

Delta sleep-inducing peptide has been given to humans in a series of small European studies from the late 1980s and 1990s, typically as an intravenous dose around 25 nmol/kg. Those studies are the only human dosing evidence, several of them reported no effect on the endocrine endpoints measured, and no trial has been registered or published since. There is no approved product and no established regimen.

Limited Human Evidence

Dosage evidence summary for Delta Sleep-Inducing Peptide (DSIP)
Human dosing established	Yes
Studied dose range	About 25 nmol/kg intravenously (weight-based)
Route	Intravenous
Frequency	Single administrations in the published studies
Duration studied	Short study protocols
Evidence level	Limited Human Evidence
Last reviewed	2026-09-05

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Delta Sleep-Inducing Peptide (DSIP), one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
Chronic insomnia study (1992)Clinical trial · Placebo-controlled clinical study	Chronic insomniac patients	25 nmol/kg body weight	Intravenous	In the afternoon before the 3rd, 4th and 5th night	Three administrations across a sleep-laboratory protocol	Sleep architecture	Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. Neuropsychobiology. 1992.
Endocrine response study (1993)Clinical trial · Controlled endocrine study with a negative result	Human volunteers	Per study protocol	Intravenous	—	—	Growth hormone and other endocrine responses — no influence found	Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion. Psychoneuroendocrinology. 1993.
Anaesthesia study (2009)Clinical trial · Clinical study	Surgical patients	Per study protocol	Intravenous	—	—	Bispectral index and electroencephalogram changes	Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol. 2009.
Opioid detoxification, open clinical trial (1998)Clinical trial · Open clinical trial	Patients undergoing opioid detoxification	Per study protocol	Intravenous	—	—	Withdrawal symptoms	Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. J Clin Psychopharmacol. 1998.

Where sources disagree

The published human dose is weight-based and intravenous, around 25 nmol/kg. DSIP is sold for subcutaneous injection with fixed protocols commonly quoted at 100–500 mcg; those figures do not come from the published studies and the route differs.
Several of the human studies are explicitly negative — DSIP did not influence growth hormone, prolactin, or meal-induced ACTH and cortisol responses. Secondary sources frequently cite this literature as support for hormonal or recovery benefits without noting that the measured endpoints did not change.
The human literature is largely three decades old and was not followed by registered trials. Absence of newer evidence is not evidence of a dose.